Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
Eiji IwamaYasushi GotoHaruyasu MurakamiShinsuke TsumuraHiroyuki SakashitaYoshiaki MoriNoriaki NakagakiYuka FujitaMasahiro SeikeAkihiro BesshoManabu OnoMasaru NishitsujiHiroaki AkamatsuRyotaro MorinagaTakanori AkagiTakayuki ShimoseShoji TokunagaNobuyuki YamamotoYoichi NakanishiKenji SugioIsamu OkamotoPublished in: The oncologist (2019)
Alectinib showed a pronounced survival benefit for patients with ALK rearrangement-positive NSCLC and a poor PS regardless of the presence of CNS metastases, a patient population for which chemotherapy is not indicated.